Increased baseline values of the acute-phase reactant C-reactive protein (CRP) are significantly associated with future cardiovascular disease, and some in vitro studies have claimed that human CRP (hCRP) has proatherogenic effects. In vivo studies in apolipoprotein E-deficient mouse models, however, have given conflicting results. We bred atherosclerosis-prone mice (Apob 100/100 Ldlr ؊/؊ ), which have human-like hypercholesterolemia, with hCRP transgenic mice (hCRP ؉/0 ) and studied lesion development at 15, 30, 40, and 50 weeks of age. Atherosclerotic lesions were smaller in hCRP ؉/0 Apob 100/100 Ldlr ؊/؊ mice than in hCRP 0/0 Apob 100/100 Ldlr ؊/؊ controls, as judged from the lesion surface areas of pinned-out aortas from mice at 40 and 50 weeks of age. In lesions from 40-week-old mice, mRNA expression levels of several genes in the proteasome degradation pathway were higher in hCRP ؉/0 Apob 100/100 Ldlr ؊/؊ mice than in littermate controls, as shown by global gene expression profiles. These results were confirmed by real-time PCR, which also indicated that the activities of those genes were the same at 30 and 40 weeks in hCRP ؉/0 Apob 100/100 Ldlr ؊/؊ mice but were significantly lower at 40 weeks than at 30 weeks in controls. Our results show that hCRP is not proatherogenic but instead slows atherogenesis, possibly through proteasome-mediated protein degradation.
T he incidence of future cardiovascular disease events is greatly increased among individuals whose baseline values of serum C-reactive protein (CRP) are in the upper segment of the population distribution (1, 2) , and in vitro studies suggest that human CRP (hCRP) may have a direct role in atherogenesis (3) . To address this issue in vivo, atherosclerosis progression has been studied in apolipoprotein E knockout (Apoe Ϫ/Ϫ ) mice (4) crossbred with transgenic mice expressing human (5, 6) or rabbit CRP (7) . However, the results have been inconsistent. In one study, lesions developed faster in male hCRP transgenic mice on an Apoe Ϫ/Ϫ background than in nontransgenic Apoe Ϫ/Ϫ controls (6), but two other studies saw no effect of hCRP on atherogenesis in Apoe Ϫ/Ϫ mice (5, 7), and one study in APOE*3-Leiden mice was also negative (8) . The authors of the latter study noted that high levels of hCRP expression in mice are not physiological and that the results should be interpreted with caution (5, 7) . In a subsequent report, atherosclerosis progression was accelerated or decelerated in Apoe Ϫ/Ϫ mice, depending on whether they were treated with native or modified forms of hCRP (9) .
Apoe Ϫ/Ϫ mice have far more severe hypercholesterolemia than humans, and most of their cholesterol is contained in very low-density lipoproteins rather than in low-density lipoproteins (LDLs) as in humans. Furthermore, Apoe Ϫ/Ϫ mice are in a continuous state of low-grade systemic inflammation (10) , and the apoE protein per se can alter immune responses (11) . Thus, the Apoe Ϫ/Ϫ mouse model may not be ideal for studies of hCRP in atherosclerosis.
In this study, we investigated the effects of hCRP on lesion development in an atherosclerosis-prone mouse model with human-like hypercholesterolemia. To create this model, we bred hCRP transgenic mice (12) with LDL receptor-null mice that exclusively express apolipoprotein B100 (apoB100) (Ldlr Ϫ/Ϫ Apob 100/100 ) (13) and analyzed lesion progression at 15, 30, 40, and 50 weeks in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice and littermate controls lacking CRP expression.
Results
Basic Characteristics. Except for plasma levels of hCRP, the basic characteristics of the CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice did not differ from those of littermate controls at any time point (Table  1) . Weight increased in both groups between weeks 15 and 30. Plasma cholesterol, triglyceride, and glucose levels were stable in both groups except for a statistically nonsignificant peak at 40 weeks. Importantly, both groups had similar serum amyloid A protein (SAA) levels, which increased in both groups until week 40 and then remained stable or decreased slightly at 50 weeks. Transgenic expression of hCRP thus did not have proinflammatory effects that triggered a response by this extremely sensitive acute-phase reactant. As expected, hCRP was only detected in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice. The median serum hCRP level was 24.0 mg/liter at 15 weeks and peaked at 51.8 mg/liter at 30 weeks (P Ͻ 0.003) ( Table 1) . Atherosclerosis Development. Only occasional atherosclerotic lesions were observed in 15-week-old mice (Fig. 1A) . At 30 weeks, both focal plaques (deep red with distinct boundaries) and fatty lesions (light red with no distinct boundaries) were present in the aortic arch of both CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice and controls. Scattered fatty lesions were also found in the abdominal region. At 40 weeks, however, the lesions were significantly larger in the controls (P ϭ 0.027) (Fig. 1B) , and only the controls had plaques in the abdominal aorta, reflecting further expansion of the lesions. In CRP-positive mice, the mean lesion size did not increase between 30 and 40 weeks. At 50 weeks, the extent of plaques had increased in both groups (Fig. 1B) . In CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice, the lesion surface area increased to approximately the same level as in controls at 40 weeks. In the controls, Author contributions: A.K., P.T., A.H., and J.B. designed research; A.K. and J.B. performed research; A.K., R.N., J.T., and J.B. analyzed data; and A.K. and J.B. wrote the paper.
lesion expanded further and remained significantly larger than in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice (P ϭ 0.041) (Fig. 1B) . In summary, the extent of the lesions differed in the two groups (P Ͻ 0.001), and atherosclerosis development was delayed in hCPRpositive mice.
Lesion Histology and hCRP mRNA. As expected, hCRP was detected only in lesions from CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice. hCRP could not be detected at 15 weeks but was clearly visible at 30 weeks, increased markedly at 40 weeks, and remained stable or decreased slightly at 50 weeks ( Fig. 2A) . The protein pattern was in accordance with hCRP mRNA levels at 30 and 40 weeks (data not shown). Complement component 3 (C3) followed a similar pattern in both groups, except that the staining was more focal in the controls. In both groups, CD68 staining was occasionally detected in 15-week lesions and then increased with lesion size over time; the extent of staining did not differ between groups (Fig. 2 A) . The same pattern was observed for Oil Red O and collagen staining (Fig. 2B) , except that the area of collagen staining was Ϸ10% larger in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice than in controls at 50 weeks (n ϭ 5 per group; P Ͻ 0.05).
Global Gene Expression and RT-PCR Validation.
To identify differences in lesion mRNA levels that could explain the slower plaque development in hCRP ϩ/0 Apob 100/100 Ldlr Ϫ/Ϫ mice, we performed microarray studies in four mice from each group by using Mouse Genome 430 2.0 GeneChips (Affymetrix, Santa Clara, CA). Seven hundred forty-two differentially expressed atherosclerosis genes were identified [local false discovery rate (LFDR) Ͻ0.25 or uncorrected P Ϸ 0.02]. Gene Ontology analysis of these genes Values are mean Ϯ SD and median (25th to 75th percentiles) in parentheses for SAA and CRP. There were no significant differences between the groups (CRP ϩ/0 vs. CRP 0/0 ) or within the groups between time points except for CRP, P Ͻ 0.003. ( Fig. 3A) using DAVID software (http://david.abcc.ncifcrf.gov) revealed significant activity in the biological processes ''protein catabolism'' (P ϭ 1.81 ϫ 10 Ϫ5 ), ''cellular macromolecule catabolism'' (P ϭ 5.23 ϫ 10 Ϫ6 ), and ''biopolymer catabolism'' (P ϭ 1.12 ϫ 10 Ϫ5 ); in the molecular functions ''proteasome endopeptidase activity'' (P ϭ 4.48 ϫ 10 Ϫ15 ); and in the cellular components ''proteasome core complex'' (P ϭ 8.34 ϫ 10 Ϫ15 ). These findings, together with the KEGG pathway analysis (''proteasome''; P ϭ 3.91 ϫ 10 Ϫ15 ), strongly indicated that the altered activity in the proteasome degradation pathway was central. Gene set enrichment analysis, a statistical approach that, unlike Gene Ontology analysis, considers the entire GeneChip dataset [supporting information (SI) Appendix 1] rather than the differentially expressed genes only (LFDR Ͻ 0.25), was used for validation. The gene set enrichment analysis revealed that mRNA levels of the genes in the proteasome degradation pathway were consistently higher in hCRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice than in controls (Fig. 3B) .
To validate the gene expression changes identified by GeneChip analysis, we used real-time PCR to examine mRNA from atherosclerotic lesions in 13 hCRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 (30 weeks, n ϭ 5; 40 weeks, n ϭ 8) and 15 littermate controls (30 weeks, n ϭ 7; 40 weeks, n ϭ 8). Specifically, we examined six genes encoding proteins central to proteasome degradation: the 20s proteasome subunits PSMA7, PSMB7, and PSMB9 (immunoproteasome subunit), the 19s proteasome cap unit PSMC6, the 11s proteasome cap unit PSME2, and E2 ubiquitin ligase (UBE2D3). Between 30 and 40 weeks, the mRNA levels of those genes were stable in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice but decreased significantly in controls (Fig. 3C) . The levels were similar at 30 weeks in both groups (P Ͼ 0.22 for all genes). At 40 weeks, however, the levels were 1.3-to 2-fold higher in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 than in controls (PSME2, P ϭ 0.04; PSMB7, P ϭ 0.053; PSMA7, P ϭ 0.066; PSMB9, P ϭ 0.074; PSMC6, P ϭ 0.08; Ube2D3, P ϭ 0.12), reaching borderline significance.
Discussion
This study shows that transgenic expression of hCRP slows lesion progression in an atherosclerosis-prone mouse model with human-like hypercholesterolemia. Thus, hCRP was not proatherogenic but appeared to be atheroprotective. The slower progression was not associated with major changes in lesion histology; however, as the lesions expanded in mice lacking hCRP, the activity of several genes in the proteasome degradation pathway decreased, as judged by mRNA levels. Whether the proteasome degradation activity level is coupled to the presence of hCRP in the lesion and whether it slows atherosclerosis development remain to be shown.
Previous studies of CRP in atherogenesis in mice have been inconclusive. For instance, the atherosclerotic lesion area in Apoe Ϫ/Ϫ mice, as determined by Oil Red O staining of aortic root sections, was larger in hCRP transgenic mice than in controls (6) . In contrast, two other studies of Apoe Ϫ/Ϫ mice (5, 7) and one of APOE*3-Leiden mice (8) did not detect a difference in the lesion area in the aortic root. Similarly, we could not detect a difference in the lesion area in aortic root sections in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice and controls. However, lesion areas in the entire aortic tree expanded more slowly in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice than in nontransgenic controls, as judged by en face analysis. In contrast, a previous en face analysis of CRP ϩ/0 Apoe Ϫ/Ϫ mice showed that hCRP accelerated lesion expansion in the aortic tree (6) .
These conflicting results suggest that the effects of CRP in atherosclerosis are dependent on the mouse model used. In support of this notion, Apoe Ϫ/Ϫ mice have altered immune responses that may directly involve apoE, including phagocytosis of apoptotic bodies, altered macrophage dynamics (10) , and altered antigen presentation efficiency (15) . Also, the effects of CRP on lesion development may be influenced by differences in the degree and type of lipoproteinemia in the mouse models. For instance, hCRP has a binding preference for LDLs rather than very low-density lipoproteins (16) . Thus, the atheroprotective role of hCRP we observed may be masked in Apoe Ϫ/Ϫ mice because they are very low-density lipoprotein animals and have altered immune functions.
In our study, collagen was slightly more abundant in the lesions of CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice than in controls at 50 weeks, consistent with the findings of Paul et al. (6) in CRP transgenic mice. The CRP mice in that study also had increases in C3 deposits and macrophages (i.e., CD68). However, in our study, neither C3 deposits nor CD68 staining of lesions differed in CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 mice and controls, although the C3 deposits appeared to be more focal in controls at 40 weeks and even more so at 50 weeks (Fig. 2) . In the only other mouse study of CRP in relation to atherogenesis in which C3 was investigated, Hirschfield et al. (5) showed no difference in lesion C3 deposits or in CD68 staining. We also detected hCRP protein in the lesions of CRP The slower development of atherosclerosis in our hCRP transgenic mice may be explained, at least in part, by persistently high levels of proteasome activity. hCRP binds to modified LDL and could thereby promote its uptake by cells and clearance from the plaques (17, 18) . The proteasome degradation pathway is a central component of the ubiquitin proteasome system, which degrades oxidized and misfolded proteins in the cell (19, 20) and regulates pathways of inflammation, cell proliferation, and apoptosis (20) . In a recent study of carotid plaques, decreased proteasome activity was a hallmark of patients with cerebral symptoms, and the activity was lowest in patients who had already suffered a stroke (21) . Decreased proteasome degradation activity has also been implicated in immunopresentation to T cells via the MHC-I pathway. It was thought that immunopresentation via this pathway was mainly restricted to intracellular proteins, but recent data strongly support cross-presentation between the MHC-I and MHC-II pathways, in which proteins are delivered to the proteasomes by endocytosis (22, 23) . Interestingly, the transport protein SEC61, which is thought to facilitate cross-presentation, was highly up-regulated in CRP transgenic mice (24) . It should be noted that the observed differences in mRNA levels of lesion proteasomes between the study groups could, alternatively to actual gene expression differences, be a consequence of differences in plaque burden and/or cellular composition of the plaque.
In summary, by using an atherosclerosis-prone mouse model with human-like hypercholesterolemia, we show that human CRP is antiatherogenic, not proatherogenic, and slows the development of atherosclerosis.
Materials and Methods
Study Mice. The Ldlr Ϫ/Ϫ Apob 100/100 mouse model has a plasma lipoprotein profile similar to that of familial hypercholesterolemia, which causes rapid progression of atherosclerosis (25 RNA Isolation and GeneChip Analysis. Aortas were perfused with RNAlater (Qiagen, Valencia, CA), and the thoracic aorta from the third rib to the aortic root was carefully dissected and homogenized with FastPrep (Qbiogene, Montreal, Canada). Total RNA was isolated with RNeasy Mini Kits (Qiagen) including a DNase I treatment step. RNA quality was assessed with a Bioanalyzer 2100 (Agilent, Palo Alto, CA). High-quality RNA samples from four CRP ϩ/0 Ldlr Ϫ/Ϫ Apob 100/100 and four littermate controls were used for expression analyses with Mouse Genome 430 2.0 GeneChips (Affymetrix). All samples were prepared with the two-cycle protocol recommended by the manufacturer. Arrays were scanned with GeneChip Scanner 3000 and analyzed with GeneChip Operating Software (Affymetrix).
Real-Time PCR. Total RNA (0.3 g) was reverse transcribed with SuperScript II according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). After dilution of the cDNA to 65 l, 3 l of cDNA were amplified by real-time PCR with 1ϫ TaqMan universal PCR master mix (Applied Biosystems, Foster City, CA). Assayon-Demand kits containing primers and probes for hCRP (Hs00357041m1), PSMA7 (Mm00478829m1), PSMB7 (Mm01327044m1), PSMB9 (Mm00479004m1), PSMC6 (Mm00458820m1), PSME2 (Mm01702833g1), Ube2D3 (Mm01318861m1), and the housekeeping genes ARBP (Mm00725448s1) and cyclophilin A (forward, GGCCGATGAC-GAGCCC; reverse, GTCTTTGGAACTTTGTCTGCAA; probe, TGGGCCGCGTCTCCTTCGA) were from Applied Biosystems.
Statistical Analysis. Differences in normally distributed parameters such as the mRNA levels of selected genes, plasma measurements, and lesion surface areas between time points/ genotypes, were analyzed with unpaired t tests. Nonparametric tests (Kruskal-Wallis) were used for plasma CRP and SAA. Microarray data were normalized at the probe level with the quantile normalization method (28) . Signal-level data were computed with the robust multichip average method (29) for 16,607 probe sets constructed by sequence matching against Refseq NM transcripts, as described (30) . The data were logtransformed, and differential expression was assessed with the regularized t statistic (31) . LFDRs were computed with the empirical Bayes method of Efron et al. (31) . All analyses were implemented in Mathematica 5.1 (Wolfram Research, Champaign, IL). DAVID software was used to assess Gene Ontology and Kegg pathways (see also SI Appendix 1). Gene set enrichment analysis (SI Appendix 1) (14, 32) was performed as an independent test of the empirical Bayes method.
